Danaher (DHR) reported solid first-quarter results before the opening bell Thursday. And while the company is seeing a solid boost from Covid testing, its core business continues to grow at a healthy clip.
The medical diagnostics and health technology company posted revenue of $7.69 billion, outpacing the $7.54 billion consensus. That represents 12% annual core growth, above the 10.4% expected by the Street. On the bottom line, earnings of $2.76 per share, an increase of 9.5% year-over-year, exceeded the $2.68 per share expected.